Publication | Open Access

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Neoadjuvant TherapyCheckmate 141MedicineTumor Pd-l1 ExpressionPathologyImmune Checkpoint InhibitorHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation OncologyMolecular Oncology